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Mutations in components of the major spliceosome have been described in disorders with craniofacial anomalies, e.g., Nager syndrome
andmandibulofacial dysostosis type Guion-Almeida. The U5 spliceosomal complex of eight highly conserved proteins is critical for pre-
mRNA splicing. We identified biallelic mutations in TXNL4A, a member of this complex, in individuals with Burn-McKeown syndrome
(BMKS). This rare condition is characterized by bilateral choanal atresia, hearing loss, cleft lip and/or palate, and other craniofacial dys-
morphisms. Mutations were found in 9 of 11 affected families. In 8 families, affected individuals carried a rare loss-of-functionmutation
(nonsense, frameshift, or microdeletion) on one allele and a low-frequency 34 bp deletion (allele frequency 0.76%) in the core promoter
region on the other allele. In a single highly consanguineous family, formerly diagnosed as oculo-oto-facial dysplasia, the four affected
individuals were homozygous for a 34 bp promoter deletion, which differed from the promoter deletion in the other families. Reporter
gene and in vivo assays showed that the promoter deletions led to reduced expression of TXNL4A. Depletion of TXNL4A (Dib1) in yeast
demonstrated reduced assembly of the tri-snRNP complex. Our results indicate that BMKS is an autosomal-recessive condition, which is
frequently caused by compound heterozygosity of low-frequency promoter deletions in combination with very rare loss-of-function
mutations.Burn-McKeown syndrome (BMKS [MIM 608572]) is a rare
condition with normal intellectual development and the
characteristic combination of choanal atresia, sensori-
neural deafness, cardiac defects, and typical craniofacial
dysmorphisms, consisting of narrow palpebral fissures, co-
loboma of the lower eyelids, a prominent nose with high
nasal bridge, short philtrum, cleft lip and/or palate, and
large and protruding ears.1–3 It has been suggested that
oculo-oto-facial dysplasia (OOFD [MIM 610332]), reported
in a large consanguineous native Alaskan family, is part of
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inheritance mode, with a single affected individual re-
ported with a ring chromosome 18.1
To identify the genetic basis of BMKS, we investi-
gated affected individuals from 11 families (BMKS001–
BMKS011) (Table 1, Figure 1, and Figure S1 available
online) by whole-exome sequencing (WES) and whole-
genome sequencing (WGS) and tested for gene dosage al-
terations by microarray and MLPA analysis. We obtained
a written informed consent from the families for participa-
tion in this study. The study was performed according to-Essen, 45122 Essen, Germany; 2Manchester Centre for Genomic Medicine,
niversity of Manchester and Central Manchester University Hospitals NHS
anchesterM13 9WL, UK; 3Institute of HumanGenetics, Helmholtz Zentrum
ical Neurophysiology, Center for Parkinson’s Disease and Movement Disor-
or Clinical Chemistry and Laboratory Diagnostics, University Hospital Jena,
de Lille, Lille 59037, France; 7Department of Genetics, University Medical
; 8Department of Medical Genetics, Dr. Behcet Uz Children’s Hospital, Izmir
105, USA; 10Seattle Children’s Hospital, Seattle, WA 98105, USA; 11Institute
t of Genomics, Life and Brain Center, University of Bonn, 53127 Bonn, Ger-
zig, Germany; 14Universita¨tsklinik fu¨r Kinderheilkunde, Abteilung Human-
cs Hospital of Ribeirao Preto, University of Sao Paulo, Sao Paulo 14048900,
burg, 93053 Regensburg, Germany; 17Institut fu¨r Praenatale Medizin & Hu-
emiology and Institute of Epidemiology II, Helmholtz Zentrum Mu¨nchen
anchester, Michael Smith Building, Oxford Road, Manchester M13 9PT,
Munich, Germany; 21Institute of Genetic Medicine, Newcastle University,
y of Human Genetics. All rights reserved.
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Table 1. Clinical Findings in Individuals with BMKS
Family BMKS001 BMKS001 BMKS002 BMKS004 BMKS005 BMKS006 BMKS007 BMKS007 BMKS008 BMKS009 BMKS010 Total
Individual III/1 III/2 II/1 II/1 II/4 II/1 II/1 II/2 II/1 II/1 14
Sex M M M F F F M M 2 F, 2 M F M 6 F, 8 M
Positive family history þ þ     þ þ þ   5/14
Hypertelorism þ þ þ þ þ þ þ þ 2/4 þ þ 12/14
Short palpebral fissures þ þ þ þ þ þ þ  4/4 þ þ 14/14
Defect of lower eyelids þ þ þ  þ  þ  4/4 þ þ 12/14
Prominent nasal bridge þ þ þ þ  þ þ þ 4/4 þ þ 13/14
Short philtrum þ þ þ þ þ þ þ þ 2/4 þ þ 12/14
Thin lips þ (þ)   þ  þ þ 1/4 þ þ 8/14
Cleft lip or palate   þ þ þ    3/4 þ þ 8/14
Bifid uvula þ        1/4   2/14
Bilateral choanal
atresia/stenosis
þ þ þ þ þ þ þ þ 4/4 þ þ 14/14
Prominent ears þ þ  þ þ  þ þ 2/4 þ þ 10/14
Preauricular tags  þ  þ þ þ   4/4   8/14
Micrognathia    þ   þ þ 4/4 þ þ 9/14
Cardiac defect    þ þ  þ  1/4   4/14
Hearing loss þ  þ þ   þ þ 4/4 þ  10/14
Normal psychomotor
development
þ þ þ (þ) þ þ þ þ 4/4 þ þ 13/14
Short stature    þ þ  þ  0/4   2/14
Others unilateral
renal
agenesis
bilateral aplasia
of lacrimal ducts,
amblyopia on the
left, microstomia
absent l cochlear nerve,
reduced right (implant
not possible)
inguinal hernia,
right eye: herniation
into right chamber
inguinal
hernia
syndactyly
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Figure 1. Pedigrees of Individuals with BMKS and Biallelic
Mutations in TXNL4A
(A) Family BMKS001 with two affected brothers (III/1 and III/2)
with a maternally inherited promoter deletion and a paternally
inherited frameshift mutation, p.Glu117* (previously published
in Wieczorek et al.2).
(B) Family BMKS002 with an affected male individual (II/1) car-
rying a maternal promotor deletion and a paternal frameshift
mutation, p.Gln13*.
(C) Family BMKS004 with an affected female individual (II/1) car-
rying a promoter deletion on one and a 1.2 Mb terminal deletion
18q23 (chr18: 76,854,774_78,077,248del) on the other allele.
Mother does not carry both deletions; father’s DNA is unavailable.
(D) Family BMKS005 with an affected female individual (II/4) with
a paternal promoter deletion and a maternal frameshift mutation,
p.Val44Alafs*48.
(E) Family BMKS006 with an affected female individual (II/1) car-
rying a paternal promoter deletion and a largematernally inherited
interstitial 18q deletion (chr18: 77,421,290_77,904,990del).
(F) Family BMKS007 with two affected brothers (II/1 and II/2)
carrying the maternal promoter deletion and a large terminal
deletion 18q (chr18: 76,841,645_78,077,248del) (previously pub-
lished in Burn et al.1).
(G) Family BMKS009 with an affected female individual with a
maternal promoter deletion and ring chromosome 18 resulting
in a 18q deletion (chr18: 73,376,178_78,077,248del) (published
in Burn et al.1). Paternal DNA was not available.
(H) Family BMKS010 with an affected male individual with pro-
moter deletion and single exon deletion 3. DNA was not available
from both parents.
700 The American Journal of Human Genetics 95, 698–707, Decembthe Declaration of Helsinki protocols and was approved
by the local institutional review board (ethical votum 12-
5089-BO for CRANIRARE).
The clinical data of the two affected brothers (III/1 and
III/2) of German family BMKS001 were published in
2003 (Figures 2A and 2B).2 The affected individual of
BMKS002 is a 34-year-old Swiss male who had the initial
clinical diagnosis of Treacher Collins syndrome (TCS
[MIM 154500]). He had bilateral choanal atresia and bilat-
eral cleft lip and palate. No internal malformations have
been reported (Figures 2C and 2D). The girl of family
BMKS003 is the first child of Turkish, nonconsanguineous
parents. She had facial dysmorphism and cleft palate
compatible with BMKS (Figures S2A and S2B, Table S1).
In addition, she had imperforate anus, persistent ductus
arteriosus, deafness, fifth finger clinodactyly, and hallux
valgus. The affected girl of family BMKS004 originates
from Vietnam. She had bilateral choanal atresia and a pat-
ent foramen ovale, which closed spontaneously (Figures 2E
and 2F). The affected girl of family BMKS005 is the fourth
child of healthy, consanguineous parents of Pakistani
origin. The possibility of a right-sided cleft lip and palate
was noted on the 20 weeks antenatal ultrasound scan.
This diagnosis was confirmed at birth (Figures 2G and
2H). She was considered to have membranous choanal
atresia, but no intervention was required. The neonatal
hearing test revealed significant hearing loss. In Dutch
family BMKS006, the girl is the only affected in her family.
She had breathing problems because of bilateral choanal
atresia. She presented with short palpebral fissures, lower
eyelid coloboma, slight left ptosis, high vaulted palate,
and three preauricular tags at left side (Figures 2I and 2J).
Family BMKS007 is one of the original Burn-McKeown
syndrome families, case 1 and case 2, previously published
by Burn et al.1 Current photographs are shown in Figures
2K and 2L. Pedigree BMKS008 is the family previously pub-
lished with oculo-oto-facial dysplasia.4 The index of family
BMKS009 is case 5 of the original Burn-McKeown syn-
drome paper1 with ring chromosome 18 (Figures 2M and
2N). BMKS010 is a French boy aged 3 years, 8 months,
born to healthy parents. He had bilateral choanal atresia
and a unilateral cleft lip. No internal malformations have
been reported. The girl of family BMKS011 was born to
healthy Brazilian parents. She had bilateral choanal atresia
and a patent ductus arteriosus. Prominent ears and hearing
loss were also diagnosed (Figures S2C and S2D; Table S1).
Whole-genome microarray or MLPA analysis was per-
formed in 11 families. Array analysis for the individuals
of families BMKS001, BMKS002, BMKS003, BMKS004,
and BMKS011 was performed with CytoScanHD Array
(Affymetrix) and evaluated with Affymetrix Chromosome
Analysis Suite v.2.0. In family BMKS006, an Agilent
180 K custom HD-DGH microarray was performed accord-
ing to manufacturer’s instructions. Array results were
confirmed by qPCR assays, designed with the Universal
ProbeLibrary Assay Design Tools (Roche Applied Science).
The qPCR analyses were performed in the parents—ifer 4, 2014
Figure 2. Facial Phenotype of Individuals with BMKS
(A and B) Persons III/1 and III/2 of family BMKS0013.
(C and D) Person II/1 of family BMKS002.
(E and F) Person II/1 of family BMKS004.
(G and H) Person II/4 of family BMKS005.
(I and J) Person II/1 of family BMKS006.
(K and L) Persons II/1 and II/2 of family BMKS007.
Note the craniofacial similarities including narrow palpebral fissures with coloboma of lower eyelids, high nasal bridge, short philtrum,
small mouth, small chin, and large and protruding ears.
(M and N) Person BMKS009 in adulthood with narrow and upslanting palpebral fissures, high nasal bridge, and short philtrum.
Consent for the publication of photographs was obtained for these individuals.DNA was available—as well. Array analysis for the individ-
uals of families BMKS005, BMKS008, and BMKS010 was
performed with Genome-Wide Human SNP Array v.6.0
(Affymetrix) according to the manufacturer’s protocol. Ge-
notypes and copy number data were generated within the
Affymetrix Genotyping Console (v.4.1.3.840) via the Bird-
seed V2 algorithm and SNP 6.0 CN/LOH algorithm, respec-
tively. For families BMKS007 and BMKS009, array analysis
was undertaken on the Agilent 8x60k oligo array (ISCA
v.2.0, Agilent Technologies UK) and analyzed with Blue-
Fuse Multi v.3.3.We developed amultiplex ligation-depen-
dent probe amplification (MLPA) assay for TXNL4A and its
promoter region. It contains one probe for each of the
gene’s three exons as well as a probe targeting the promoter
distal to the 34 bp deletion (Figure S3). Oligonucleotides
for MLPA were purchased at MWG Eurofins. MLPA re-The Americanagents were from MRC-Holland. MLPA reactions were per-
formed according to standard protocols as provided by
MRC-Holland, and analysis of data was carried out as
described.7
Copy-number analyses by microarray analysis revealed
five heterozygous microdeletions at 18q23, all including
TXNL4A (MIM 611595) (Table 2, Figures 3 and S3). Two
identical terminal deletions of 1.2 Mb were found in fam-
ilies BMKS004 and BMKS007 and an interstitial deletion
of 0.48 Mb in family BMKS006. In a person originally
described by Burn and colleagues1 (BMKS009), the ring
chromosome 18 is associated with a terminal deletion of
4.7 Mb. In addition, we hypothesized that smaller dele-
tions might be also present in individuals with BMKS
and established an MLPA. This revealed a single heterozy-
gous exon 3 deletion of TXNL4A in family BMKS010.Journal of Human Genetics 95, 698–707, December 4, 2014 701
Figure 3. Gene Structure of TXNL4A with Identified Mutations and Deletions
The heterozygous deletions comprising TXNL4A identified in the index individuals of families BMKS009, BMKS007, BMKS004, and
BMKS006 with a size of 4.7 Mb, 1.147 Mb, 1.164 Mb, and 0.484 Mb, respectively, are shown at the top of the figure. The gene structure
with the identified mutation in families BMKS001, BMKS002, and BMKS005 are shown at the bottom as well as the exon 3 deletion of
family BMKS010.Parental DNA was available in two families (BMKS007 and
BMKS006), and the respective deletions were inherited
from a healthy parent.
To identify the causative gene under the assumption of an
autosomal-dominant mode of inheritance with reduced
penetrance, we then investigated five affected individuals
from four families by exome sequencing8 (BMKS001,
BMKS002,BMKS003, andBMKS005) inwhom18q23micro-
deletions had been excluded. We identified heterozygous
TXNL4A loss-of-function mutations in three families:
nonsense mutations were identified in families BMKS001
and BMKS002 (RefSeq accession number NM_006701.2;
c.349G>T [p.Glu117*] and RefSeq NM_006701.2; c.37C>T
[p.Gln13*], respectively). A frameshiftmutationwas present
in family BMKS005 (RefSeq NM_006701.2; c.131delT
[p.Val44Alafs*48]) (Table 2, Figure 3). All mutations in the
index persons were confirmed and the segregation analyses
within the families were performed by Sanger sequencing.
None of thesemutationswere present in the 1000Genomes
Project9 data, in dbSNP, or in 3,000 in-house control exomes
from individuals with unrelated diseases. However, as in
the case of the microdeletions, all intragenic TXNL4A
mutations were inherited and also found in healthy par-
ents, grandparents, and siblings of the affected individuals
investigated.
The recurrent observation of heterozygous TXNL4A loss-
of-function mutations in unaffected family members
(Figure 1) made haploinsufficiency unlikely as the dis-702 The American Journal of Human Genetics 95, 698–707, Decembease-causing mechanism. Moreover, the unaffected sib-
lings in the consanguineous family, BMKS005, shared a
different haplotype across the TXNL4A locus compared
to the affected child, suggesting that a second variant at
this locus remained undetected.
We then set out to search for genomic noncoding vari-
ants contributing to BMKS and performed whole-genome
sequencing (WGS) in six affected individuals from five
families (BMKS001, BMKS002, BMKS004, BMKS005, and
BMKS008).4 Libraries for genome sequencing were pre-
pared with PCR-free protocols (TruSeq DNA PCR-Free, Illu-
mina). Sequencing was performed as 100 bp paired-end
reads on HiSeq2000/2500 systems (Illumina). For the ge-
nomes, we generated on average 150 Gb of sequence re-
sulting in an average depth of coverage of 45 with 98%
of RefSeq coding region covered at least 20 times. Image
analysis and base calling was performed with Illumina
Real Time Analysis. Reads were aligned against the human
assembly hg19 (GRCh37) via Burrows-Wheeler Aligner
(BWA v.0.6.2). We performed variant calling specifically
for the regions targeted by the exome enrichment kit, by
using SAMtools (v.0.1.18), PINDEL (v.0.2.4t), ExomeDepth
(v.0.1), and custom scripts. In case of genome sequences,
we used CNVnator (v.0.2.7) and BreakDancer (v.1.1.2)
instead of ExomeDepth to detect structural variants.
Variant quality was determined with the SAMtools varFil-
ter script. We used default parameters, with the exception
of the minimum p value for base quality bias (2), whicher 4, 2014
Table 2. Mutations and Deletions Identified in TXNL4A
Pedigree and Individual 1st Mutation Origin 2nd mutation Origin
BMKS001, III/1 & III/2 chr18: g.77,733,765C>A, c.349G>T (p.Glu117*), exon 3 pat (pat GM) promoter D 1 mat (mat GF)
BMKS002 chr18: g.77,748,356G>A, c.37C>T (p.Gln13*), exon 1 pat promoter D 1 mat
BMKS003 Ø Ø
BMKS004 WGS[hg19] 18q23(76,854,774–78,077,248)x1 ¼ > D 1.222 Mb,
del(18)(q23/qter)
? (not mat) promoter D 1 ? (not mat)
BMKS005 chr18: g.77,748,262delA, c.131delT (p.Val44Alafs*48), exon 1 mat promoter D 1 pat
BMKS006 arr[hg19] 18q23(77,421,290–77,904,990)x1, D 0.484 Mb mat promoter D 1 pat
BMKS007, II/1 & II/2 WGS[hg19] 18q23(76,841,645–78,077,248)x1 ¼ > D 1.235 Mb,
del(18)(q23/qter)
pat promoter D 1 mat
BMKS008 promoter D 2 mat, pat promoter D 2 pat, mat
BMKS009 46,XX,r(18)(p14q23) arr[hg19] 18q23(73,376,178–78,077,248)x1 ¼
> D 4.701 Mb, del(18)(q23/qter)
de novo promoter D 1 mat
BMKS010 D of exon 3 of TXNL4A (MLPA) ? (par. n. avail.) promoter D 1 ? (par. n. avail.)
BMKS011 Ø Ø
The WGS sequences extend up to 78,017,154 where the terminal repeat region starts. The position of the endpoints for the terminal deletions are set to
78,077,248 according to the length of chromosome 18 (CRCh37/hg19). TXNL4A reference sequence is RefSeq NM_006701.2.
promoter D 1: WGS[hg19] chr18: g.77,748,581_77,748,614delCGCCGTGCGTGCTGACGGCATGCGCGCGCGCTAG
promoter D 2: WGS[hg19] chr18: g.77,748,604_77,748,637delGCGCGCGCTAGCGCCGTGCGTGCTGACGGCATGT
The overlap of the promoter D 1 and promoter D 2 deletions is underlined.
Abbreviations are as follows: pat, paternal; mat, maternal; GF, grandfather; GM, grandmother: Ø, no mutation found; WGS, whole-genome sequencing.we set to 1 3 10400. Additionally, we applied a custom
script to mark all variants having adjacent bases of lowme-
dian base quality. All variants were then annotated with
custom Perl scripts. Annotation included information
about known transcripts (UCSC Known Genes and RefSeq
genes), known variants (dbSNP v.135), type of mutation,
and—if applicable—amino acid change in the correspond-
ing protein. The annotated variants were inserted into
an in-house database. To discover putative disease-causing
variants, we queried the database to show only variants
with a minor allele frequency less than 1%. To reduce false
positives, we filtered out variants that had a variant quality
of less than 30 or didn’t pass the filter scripts. We then
manually checked the raw read data of the remaining
variants with the Integrative Genomics Viewer (IGV). In
the affected individuals of families BMKS001, BMKS002,
BMKS004, and BMKS005, we identified a common hetero-
zygous 34 base pairs (bp) deletion (chr18: 77,748,581–
77,748,614, hg19) in the putative promoter region of
TXNL4A (Figure S4). We denote this deletion as type 1 D.
The putative promoter is comprised of two identical
22 bp motifs (CATGCCGTCAGCACGCACGGCG, in the
direction of transcription), which are separated by a 12
base pair spacer (CTAGCGCGCGCG) (Figure S5). This
56 bp region (chr18: 77,748,581–77,748,636, hg19) maps
49 to 105 bp upstream of the putative transcription start
site (RefSeq NM_006701.2) and contains multiple poten-
tial transcription factor binding sites. A 34 bp deletion of
the same type was also found by amplification of the
TXNL4A promoter in the affected individuals from the re-
maining four families with heterozygous microdeletionsThe American(primer sequences and PCR conditions are available on
request). Parental samples of nine affected individuals
were available for segregation analysis. In each family,
the common 34 bp deletion was inherited from the unaf-
fected parent who did not carry the null mutation (Table
2 and Figure S6).
Interestingly, the affected individual from family
BMKS0085 was homozygous for a slightly different 34 bp
deletion in the putative promoter region. It comprised
the proximal 33 bp of the 56 bp region plus the preced-
ing A nucleotide (chr18: 77,748,604–77,748,637, hg19)
(Figure S5). We denote this deletion as type 2 D. Segrega-
tion analysis in this family showed that the homozygous
promoter deletion segregated with the phenotype,
whereas all heterozygotes appeared healthy (Figure S6). It
is worth noting that the two resulting sequences of the de-
letions differed by only one nucleotide, which is the A or
G, respectively, that precedes the 22 bp repeat. Deletions
in the same region were not present in the 1000 Genomes
Project data. This is most likely due to insufficient repre-
sentation of this GC-rich region in genomic libraries that
were prepared with protocols containing PCR-amplifica-
tion steps. Thus, for example, this region was not covered
in 200 low-coverage genomes (4- to 8-fold) sequenced
in-house. We therefore analyzed 3,165 population-based
samples of German and 178 of South Asian origin by
PCR amplification and agarose gel electrophoresis. We
identified 45 heterozygous and a single homozygous
type 1 deletions as well as a single heterozygous type 2
deletion pointing to a German allele frequency of approx-
imately 0.76%. Data about the craniofacial phenotypeJournal of Human Genetics 95, 698–707, December 4, 2014 703
Figure 4. The 34 bp Deletion Reduces the Activity of the Puta-
tive TXNL4A Promoter in Dual Luciferase Assays
HEK293 cells were transfected with the reporter vector carrying
the wild-type promoter without the deletion (without del) of
TXNL4A, with either type of the 34 bp deletion (type 1 D or
type 2 D), or the reporter vector without insert (control). The vec-
tor without the deletion (magenta) functioned as promoter,
enhancing the luciferase expression by 85-fold in comparison
with the control vector (blue). However, the vector with the type
1 D (green) reduced promoter’s activity by 59% and with the
type 2 D (red) by additional 13%, resulting in a total reduction
of 72% in comparison with the vector without the deletion.
Data represent the means and standard deviations of six technical
replicates of three independent experiments and demonstrate the
fold change of the relative luciferase units (RLU) compared to the
control vector. Asterisks indicate statistically significant differ-
ences, with *p < 0.05 (Wilcoxon rank sum test).were not available for the control samples. Haplotype
analysis of the genome-sequencing data revealed that
the promoter deletions were located on different haplo-
types and, thus, that they occurred most likely due to
recurrent events rather than a founder effect (Figure S7).
Interestingly, 11 control individuals (allele frequency
0.17%) were found to be heterozygous for a 34 bp inser-
tion (chr18: 77,748,581_77,748,614dup) into the pro-
moter region (data not shown). The inserted sequence is
identical to the 34 bp cassette that resembles the type 1
D (chr18: 77,748,581–77,748,614) and thus must be re-
garded as a head-to-tail tandem duplication. This results
in a 90 bp sequence consisting of three 22 bp motifs sepa-
rated by two 12 bp spacers. These results support the
notion that this region is vulnerable to recurrent muta-
tional events.
To test the hypothesis that the region affected by the
upstream deletions exerts promoter function, we per-
formed dual luciferase reporter gene assays in HEK293
cells (Figure 4). A 585 bp construct (chr18: 77,748,330–
77,748,914) containing 382 bp of the wild-type promoter
region, the 140 bp 50-UTR, and the first 21 codons
(63 bp) of the TXNL4A gene enhanced luciferase expres-
sion 85-fold compared to the empty control vector. How-
ever, promoter activity of constructs containing the type
1 D (del1) and type 2 D (del2) was reduced by 59% and
72%, respectively, compared to the wild-type construct.
These data indicate that the 56 bp region (chr18:
77,748,581–77,748,637) indeed exerts promoter activity
and that the entire region is essential for normal activity704 The American Journal of Human Genetics 95, 698–707, Decembbecause the identified deletions result in a considerable
reduction of expression. Furthermore, the severe attenua-
tion of TXNL4A expression in case of the type 2 D might
be sufficient to cause the phenotype in homozygous indi-
viduals in family BMKS008.
We further investigated the in vivo effect of the pro-
moter deletion on TXNL4A allelic expression ratios. By
sequence analysis of reverse-transcribed TXNL4A from
persons and relatives heterozygous for a nonsense muta-
tion, we noted that these mutant transcripts escaped
nonsense-mediated mRNA decay (NMD) (not shown).
This finding was not surprising. The UAG generated by
stop mutation c.37C>T is followed by two in-frame AUGs
that can function as alternative translation start sites.
The c.131delT introduces a frameshift into the mRNA.
However, it leads to a premature stop not before the novel
codon 92, which is encoded in the last exon of TXNL4A.
Thus, it probably escapes NMD as does the transcript
with the c.349G>T (p.Glu117*) in exon 3. Primer exten-
sion analysis revealed that steady-state transcript levels of
the allele carrying the wild-type ORF and the type 1
promoter deletion are reduced compared to transcript
levels of the allele with the mutant ORF and wild-type
promoter (Figure S8). This provides further evidence that
the deletion in the promoter region negatively affects
transcription.
The U5 spliceosomal complex of eight highly conserved
proteins is critical for pre-mRNA splicing.10 The ortholo-
gous yeast gene, which is also known as DIB1/SNU16, en-
codes a highly evolutionarily conserved 138 amino acid
protein that is an essential component of the U4/U6,U5
tri-snRNP complex required for pre-mRNA splicing.11 In
yeast, null mutations are lethal. Thus, homozygous null
mutations in humans might not be compatible with life.
To investigate how reduced expression of the yeast DIB1
gene influenced the assembly of spliceosome complexes,
a haploid yeast strain was constructed with DIB1 under
control of theGAL1 promoter. Turning offDIB1 expression
resulted in reduced assembly of the U4/U6,U5 tri-snRNP
complex (Figure 5). Successful DIB1 depletion of yeast
cells is shown in Figure S9. Because DIB1 is highly homol-
ogous to TXNL4A, it is likely that reduced expression of
TXNL4A in humans would also cause reduced tri-snRNP
assembly. We hypothesize that reduced tri-snRNP assem-
bly influences the splicing of a specific subset of pre-
mRNAs, resulting in the phenotypic spectrum associated
with BMKS.
Here, we show that either compound heterozygosity of
a promoter deletion combined with a null mutation or a
homozygous promoter deletion at the TXNL4A locus
cause the majority of cases (9 of 11) of Burn-McKeown
syndrome. The index persons of two families (BMKS003
and BMKS011) had the initial diagnosis of BMKS because
of overlapping clinical findings. They are clinically not
distinguishable from the mutation-positive individuals
(Table S1). Consistent with genetic heterogeneity for
BMKS, by direct sequencing of the coding region ofer 4, 2014
Figure 5. Depletion of DIB1, the Yeast
Ortholog of TXNL4A, Results in Defective
Tri-snRNP Assembly
Yeast whole-cell splicing extract from
strain DIB1GALHA grown in galactose
(nondepleted) or glucose (Dib1 depleted)
was fractionated through a 10%–30% glyc-
erol gradient to separate spliceosome com-
plexes. RNA isolated from fractions was
subjected to primer extension to detect
the levels of the U1, U2, U4, U5, and U6
snRNAs in each fraction. The fraction
numbers are indicated at the top of each
panel. The locations of the U6 snRNP,
U4/U6 di-snRNP, U5 snRNP, and U4/
U6.U5 tri-snRNP in the fractions are indi-
cated below each panel.TXNL4A, amplification of the promoter region, microarray
analysis, and MLPA in two families (BMKS003 and
BMKS011), we did not identify TXNL4A mutations (not
shown).
The predicted frequency of homozygous carriers of the
type 1 promoter deletion of 1 in 17,300 most likely ex-
cludes this genotype as cause of BMKS. Investigations of
larger cohorts are required. This genotype might lead to a
mild phenotype, which escapes clinical notice. In addi-
tion, this observation indicates that the homozygous
type 2 deletion in pedigree BMKS008 has a stronger effect
than homozygous type 1 deletions, which is consistent
with the results in the reporter gene assays.
Among 14 individuals with BMKS, 8 presented with
cleft lip and/or cleft palate. To evaluate whether TXNL4A
mutations also contribute to nonsyndromic forms of
cleft lip and/or cleft palate, one of the most frequent
congenital human malformations, we examined 1,148The American Journal of Human Genpersons with nonsyndromic orofacial
clefting (994 with nonsyndromic
cleft lip with or without cleft palate,
154 with nonsyndromic cleft palate
only) (MIM 119530) for TXNL4A
mutations. All individuals had been
clinically assessed prior to inclu-
sion in the study as previously
described.12–14 Persons with possible
underlying syndromes, intellectual
disability, or possible prenatal con-
tributory factors such as maternal
ingestion of known teratogenic sub-
stances were not included in the
study. The ethnic background of
affected individuals and controls had
been assessed on the basis of the
grandparents’ descent. Controls were
ethnically matched. We identified 11
heterozygous type 1 deletions, four
34 bp duplications, and one 68 bp
duplication. Thus, there is no sig-
nificant difference between the fre-quency of promoter deletions/duplications among indi-
viduals with nonsydromic clefting and the control cohort.
Because the phenotype of the Treacher Collins syn-
drome15 overlaps with that of BMKS, and indeed some of
the BMKS individuals had the tentative diagnosis of TCS,
we also screened 50 individuals with TCS who do not
have mutations in any known TCS gene for mutations
and deletions at the TXNL4A locus. We identified one per-
son with a heterozygous type 2 promoter deletion, which
is in agreement with the rate of heterozygotes in our con-
trol cohort. This individual, however, did not have a sec-
ond TXNL4A mutation as determined by sequence and
MLPA analysis.
Our results further expand the number of inherited
disorders resulting from mutation of components of
the spliceosome, which besides others include Nager
syndrome (MIM 154400)16 and mandibulofacial dysos-
tosis type Guion-Almeida (MIM 610536),17 both alsoetics 95, 698–707, December 4, 2014 705
characterized by craniofacial malformations. Because all
three syndromes caused by mutations in spliceosomal
components have facial dysmorphism in common, one
can assume that craniofacial development is highly sensi-
tive to dysfunction of the spliceosome.
The unusual combination of a low-frequency regulatory
variant and a rare null mutation on the other allele has
previously been described, for example for RBM8A (MIM
605313), as the cause of thrombocytopenia-absent radius
syndrome (MIM 274000).18,19 It is tempting to speculate
that this mechanism of obligate compound heterozygosity
might underlie a number of other rare recessive conditions
where complete loss of function might be incompatible
with life.Supplemental Data
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